Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Preferred Stock Liabilities: 2023

Historic Preferred Stock Liabilities for Zenas BioPharma (ZBIO) over the last 1 years, with Dec 2023 value amounting to $250.1 million.

  • Zenas BioPharma's Preferred Stock Liabilities was N/A to $250.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $250.1 million, marking a year-over-year change of. This contributed to the annual value of $250.1 million for FY2023, which is N/A change from last year.
  • Per Zenas BioPharma's latest filing, its Preferred Stock Liabilities stood at $250.1 million for FY2023.
  • In the past 5 years, Zenas BioPharma's Preferred Stock Liabilities ranged from a high of $250.1 million in FY2023 and a low of $250.1 million during FY2023.
  • Over the past 1 years, Zenas BioPharma's median Preferred Stock Liabilities value was $250.1 million (recorded in 2023), while the average stood at $250.1 million.